-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Guangxiang Pharmaceutical: Pioneering a “Green Pharmaceutical” Model with Innovative Approaches
Category:
TIME：2019-12-03
【SUMMARY】
Shisiyao Group’s Hebei Guangxiang Pharmaceutical is seizing the opportunities presented by the coordinated development of the Beijing–Tianjin–Hebei region. Leveraging the Group’s strong financial resources, robust R&D capabilities, and established brand reputation, the company has invested in and is building a mega-scale pharmaceutical enterprise within the Beijing–Cangzhou Bohai New Area Biopharmaceutical Industrial Park, with a primary focus on active pharmaceutical ingredients, intermediate compounds, and biopharmaceutical formulations.
Shisiyao Group’s Hebei Guangxiang Pharmaceutical is seizing the opportunities presented by the coordinated development of the Beijing–Tianjin–Hebei region. Leveraging the Group’s strong financial resources, robust R&D capabilities, and established brand influence, the company is investing in and building a mega-scale pharmaceutical enterprise within the Beijing–Cangzhou Bohai New Area Biopharmaceutical Industrial Park, with a primary focus on active pharmaceutical ingredients, intermediate compounds, and biopharmaceutical formulations.
The project covers a total area of over 1,000 mu, with the first phase spanning 500 mu and a total construction area of 250,000 square meters. To date, 160,000 square meters of factory buildings and supporting facilities have been completed, with cumulative investment nearing RMB 1 billion. The primary products of the first phase include caffeine derivatives, metronidazole, nifedipine, aminophylline, and others, while the second phase will focus on the production of azithromycin, arbidol, and other related product lines as well as biopharmaceutical formulations.
Gao Shuping, Chairperson of Hebei Guangxiang Pharmaceutical Co., Ltd. under Shisiyao Group, stated that Guangxiang Pharmaceutical’s flagship caffeine product line has leveraged advanced automation and information technologies to transition from traditional batch production to continuous, intelligent manufacturing. This transformation has significantly enhanced production efficiency, product quality, and safety standards while substantially reducing pollutant emissions. In addition, the company has, for the first time, adopted hydrogenation reduction technology to replace the conventional iron powder reduction process, thereby effectively minimizing environmental pollution.
The project is built on the “green pharmaceutical” philosophy, integrating, assimilating, and applying world-leading technologies, process methodologies, and equipment for active pharmaceutical ingredient synthesis, reduction, separation, and extraction. It emphasizes key advantages and characteristics such as energy conservation and environmental protection, intensive and efficient operations, and safe production. Phase I of the project includes RMB 160 million in environmental protection investments and marks the first time in the industry that advanced technologies such as CWO, MVR, and catalytic ozone oxidation have been adopted, significantly reducing total COD emissions, improving effluent quality, and minimizing solid waste generation.
Gao Shuping stated that, with the strong support of the CPC Cangzhou Municipal Committee, the Cangzhou Municipal People’s Government, and the Party Working Committee and Management Committee of the Bohai New Area, project construction has been accelerated. Construction officially commenced in March 2018, and the facility obtained its GMP certification in September 2019, marking its official entry into production. Following the normal operation of Phase I, annual sales revenue is expected to average RMB 2.2 billion, with annual profits and taxes totaling RMB 600 million. The company is committed to building a green factory that serves as an industry- and regionally recognized model and demonstration site, thereby playing a leading role in driving high-quality development in the Cangzhou Bohai New Area.
(Sun Jiayue, Chen Lei)
Keywords:
Next
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
Business License
